Background: There are currently no robust biomarkers of chronic obstructive pulmonary disease (COPD) risk or progression. Club cell secretory protein-16 (CC-16) is associated with the clinical expression of COPD. We aimed to determine if there is a causal effect of serum CC-16 level on COPD risk and/or progression using Mendelian randomisation (MR) analysis.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is expected to be the third leading cause of death worldwide by 2030.
[1] Currently, there are no acceptable biomarkers for predicting the risk of COPD or its progression. If robust biomarkers and disease-modifying therapies are to be developed, a better understanding of the causal mechanisms underlying the risk of COPD, and its progression over time, is critical.
Club Cell Secretory Protein 16 (CC-16) is a 16 kDa pneumoprotein produced predominantly by club cells in the airway epithelium, where it appears to have a protective, anti-inflammatory effect. [2] [3] [4] Reduced CC-16 levels are associated with the clinical expression of COPD: serum, sputum, and bronchoalveolar lavage fluid (BALF) CC-16 concentrations decrease with increasing disease severity; [5] [6] [7] [8] and reduced serum CC-16 is associated with faster lung function decline. [9, 10] In a mouse model of cigarette smoke exposure, CC-16 -/knockout mice showed greater COPD-like lung changes than wild type mice. [3] However, this finding was not replicated by other investigators. [10] While this discrepancy may be explained by differences in experimental design (including the duration and dose of smoke exposure), it is clear that further efforts to establish a causal role for reduced CC- 16 in COPD pathogenesis are required.
Mendelian randomisation (MR) analysis is a promising approach to explore causality in humans by relating genetic variants to disease outcomes via a biological risk factor (e.g. protein levels). [11] Due to the random allocation of alleles at meiosis, and under the assumption that the genetic variants exert their effects on disease outcomes only via the risk factor of interest, MR analysis is relatively resistant to confounding. Furthermore, since the genomic contribution to the risk factor is constant over a lifetime, MR analysis is relatively resistant to bias due to reverse causation (where the disease itself influences the protein level). For these reasons, MR analysis is particularly attractive for establishing a potential causal role for biological factors in complex diseases such as COPD. We have previously demonstrated a potential causal effect of low surfactant protein D (SPD) in increasing COPD risk and progression using the MR framework. [12] Other molecules associated with COPD outcomes in epidemiological studies, such as C-reactive protein, [13] interleukin-6 [14] and blood eosinophil count, [15] do not yield evidence of causality when subjected to analysis by MR. Therefore, D D: What is the causal effect of CC-16 level on COPD outcomes? MR analysis (ICGC dataset, LHS, ECLIPSE) Table S1   Table 2, Figures 2,3   Table S2   Table 4 RESULTS Table 3 , Figure 4 pQTLs eQTLs 9
Genome-wide association study (GWAS) for serum CC-16 concentration
The full details of the GWAS for serum CC-16 level are outlined in the Supplementary Methods.
Briefly, we identified SNPs associated with serum CC-16 concentration (protein quantitative trait loci [pQTLs] , Analysis B in Figure 1 ) in the LHS and ECLIPSE and combined the results in an inverse variance weighted (IVW) fixed-effects meta-analysis. We identified independently-associated SNPs using conditional analysis within each 2 Mb gene region. [20] From this, we retained only SNPs having independent, genome-wide significant (p<5x10 -8 ) associations with CC-16 levels.
Associations between CC-16 pQTLs and COPD outcomes
For COPD risk, we extracted summary statistics for each CC-16 pQTL's association with the presence of COPD in the ICGC dataset. For COPD progression, we tested serum CC-16 pQTLs for possible association with changes in FEV1 over time in the LHS and ECLIPSE cohorts separately, using the LME model described previously, with the addition of the first 5 genetic principal components as covariates (Analysis C in Figure 1 ).
Mendelian randomisation (MR) analysis
To estimate the causal effect of CC-16 concentration on COPD outcomes (Analysis D in Figure 1 ), we related the CC-16 pQTL per-allele effects on serum CC-16 levels to their effects on COPD outcomes using an IVW MR model with the CC-16 pQTLs as instrumental variables, with nominal significance set at p<0.05 (see Supplementary Methods for description of the model). To test for violations of MR assumptions, [21] we tested for heterogeneity by Cochran's Q statistic, and for evidence of directional pleiotropy by both MR-Egger [22] (intercept term) and MR-PRESSO ("global test"), [23] with nominal significance of each test set at p<0.05 (see Supplementary Methods).
Lung tissue gene expression analysis
To determine if the serum CC-16 pQTLs have any effects on quantitative gene expression in lung tissue, we tested for their associations (at false discovery rate [FDR]<0.1) with mRNA transcript levels using data from the Lung eQTL Study [19] (Analysis E in Figure 1 ) (See Supplementary Methos). For this analysis, we considered only cis-eQTLs, within a region 1 Mb either side of the sentinel SNP.
Statistical software
We performed all analyses in R (version 3.4.0; www.r-project.org). [24] Table   2 ). Quantile-quantile plots showed deviation from the expected distribution at low p values (Supplementary Results Figure S3 Recombination rate (cM/Mb) Recombination rate (cM/Mb) Recombination rate (cM/Mb) (Table S2) . One pQTL (rs7962469 on chromosome 12) was significantly associated with COPD risk in the ICGC dataset (p=1.2x10 -3 ). Two pQTLs (rs3741240 and rs11231085, both on chromosome 11) were significantly associated with change in FEV1 in the LHS (p=0.047 and p=5.4x10 -4 , respectively). rs3741240 was also significantly associated with change in FEV1 in ECLIPSE (p=0.02).
RESULTS

Serum CC-16 level is associated with COPD progression
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Genetically-determined serum CC-16 level is related to COPD risk and progression
The IVW MR estimate for COPD risk in the ICGC dataset was significant (beta=-0.11, p=0.008),
suggesting a protective effect of genetically-increased serum CC-16 level on the risk of COPD (Table   3 , Figure 4A ). Tests for violation of MR assumptions were not statistically significant (Table 3 ;
Supplementary Results Figure S4 ).
The IVW MR estimate for change in FEV1 in the LHS was statistically significant (beta=7.4, p=0.02),
suggesting a protective effect of genetically-increased serum CC-16 on COPD progression (Table 3 , Figure 4B ). Again, tests for violations of MR assumptions were not statistically significant (Table 3; Supplementary Results Figure S5 ). The IVW MR estimate for change in FEV1 in the ECLIPSE study was not significant (Table 3 ; Supplementary Results Figure S6 ). 
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Multiple CC-16 pQTLs affect lung tissue gene expression
Four of the pQTLs for serum CC-16 level were also lung eQTLs (Table 4) . SNPs rs3741240 and rs11231085 on chromosome 11 were associated with levels of SCGB1A1 mRNA (p=4.13x10 -12 and p=3.82x10 -7 , respectively), with allele effects in the same direction as their effects on serum CC-16
level. SNP rs4971100 (chromosome 1) was associated with mRNA levels for the glucosylceramidase beta (GBA) gene (p=4.58x10 -8 ) in lung tissue. SNP rs7962469 (chromosome 12) was associated with ACVR1B gene expression (p=3.31x10 -116 ) with the allele effect in the same direction as its effect on serum CC-16 level. 
SNP rsID Chr Position
DISCUSSION
By performing the largest GWAS-pQTL analysis for serum-CC16 levels to date (n=5,552), we have identified many novel distal loci associated with serum CC-16 level. Furthermore, using the MR framework, we have demonstrated a potential protective effect of genetically-increased serum CC-16 level on both COPD risk and disease progression. Our lung tissue eQTL analysis suggests that genetically-increased serum CC-16 levels may be due to increased lung tissue gene expression at the CC-16-encoding gene SCGB1A1. Our findings expand upon the existing body of literature on the biology of CC-16 and support a possible causal role for CC-16 in COPD pathogenesis.
We identified genetic variants independently associated with serum CC-16 level (pQTLs) in 6 different loci across 5 chromosomes. The most significantly-associated SNP was rs3741240 (p=2.08x10-59 in the GWAS meta-analysis), which is in a non-coding region of the CC-16 gene SCGB1A1 on chromosome 11. This SNP was also the top association in the only previously-published GWAS for serum CC-16 level. [25] In the same gene region, we have identified a second, independentlyassociated SNP rs11231085 by conditional analysis (p=9.13x10-57 in the GWAS meta-analysis).
These results reflect the increased statistical power of GWAS meta-analysis to detect associated genetic variants.
To our knowledge, this is the first study to demonstrate that variants in the SCGB1A1 gene are associated with lung function decline. The SNP rs3741240 has been previously associated with both airway hyperresponsiveness [26] and asthma, [27] but was not associated with COPD outcomes in the previously-published ECLIPSE GWAS. [25] The SNP rs11231085 has not previously been associated with lung function or lung disease. Our lung tissue eQTL analysis suggests that genetically-increased serum CC-16 levels may be due to increased lung tissue expression of the SCGB1A1 gene. The precise mechanisms by which SCGB1A1 gene expression and CC-16 protein production support lung function are unclear.
The remaining genetic variants we found to be associated with serum CC-16 levels were in loci distal to the SCGB1A1 gene, and each of these associations were novel. SNP rs7962469 on chromosome 12 has been previously associated with risk of lung disease. This SNP is an intronic variant in the ACVR1B gene, which codes for a member of the transforming growth factor-beta (TGF-b) receptor superfamily also known as activin-like kinase-4 (ALK4). We found this variant was also associated 20 with lung tissue expression of ACVR1B (i.e. it is an eQTL), although how expression of the ALK4 receptor is related to serum levels of CC-16 remains unclear. Members of the TGF-b superfamily, including ALK4, are potent regulators of gene transcription, and the downstream Smad signalling pathway has been shown to be dysregulated in COPD. [28] The association between ACVR1B variants and serum CC-16 level may therefore be due to modulation of SCGB1A1 transcription by ALK4 receptor activity. Additionally, ALK4 and Smad signalling are involved in the differentiation and proliferation of lung cells including airway epithelial cells. [28] It is therefore possible that ACVR1B variants relate to CC-16 levels due to altered numbers of differentiated club cells secreting the CC-16
protein. Interestingly, variants in or near the ACVR1B gene region have been associated with lung function [29] and COPD risk. [30, 31] The rs7962469 variant, through its effects on ACVR1B expression in lung tissue, has also been causally associated with emphysema distribution on chest imaging in the COPDGene cohort. [30] The link between this gene and CC-16 biology is intriguing, and warrants further investigation.
The links between the other novel SNPs and serum CC-16 level are less clear. SNP rs1515498 on chromosome 3 is an intronic variant in the TP63 gene, which itself is related to the risk of lung cancer [32, 33] but has also recently been associated with COPD risk in a Taiwanese population. [34] SNP rs4971100 on chromosome 1 is an eQTL for the GBA gene in lung tissue, which encodes a cell membrane protein involved in lipid processing. Abnormalities in the GBA gene are associated with the lysosomal storage disorder Gaucher's disease [35] as well as the neurodegenerative disorder Parkinson disease. [36] These distal gene associations highlight the complexity of CC-16 biology.
The association between serum CC-16 levels and lung function is well-documented in observational and epidemiological studies. CC-16 may be critical to lung development. [37] Lower serum CC-16 levels have also been associated with accelerated FEV1 decline in early adulthood [38] and increased risk of incident COPD. [37] Despite the consistency of these observations, confounding through reverse causality and environmental exposures remained a possibility. Since MR analysis quantifies only the genomic contribution to serum CC-16 level, it is more resistant to confounding by these factors and argues for a unidirectional association. This is particularly important in light of the disparate effects of cigarette smoke: cumulative chronic exposure is strongly associated with reduced serum CC-16 concentration; [39] yet acute smoke exposure causes a transient increase in serum and commensurate decrease in BALF CC-16 concentration, possibly by disrupting epithelial cell integrity 21 and/or increased vascular permeability. [40] CC-16 appears to have a protective effect on the airway epithelium, [2] [3] [4] most likely through regulation of inflammation via the nuclear factor kB (NF-kB) pathway. [3] Genetic and environmental factors that reduce the availability of CC-16 in the lung may therefore increase susceptibility to inflammatory insults, with resultant airway and/or parenchymal changes leading to accelerated lung function decline.
Through MR analysis, we found a significant effect of serum CC-16 level on COPD progression in the LHS. However, we did not find a similar effect in the ECLIPSE study. Notably, the effect estimate in ECLIPSE was similar, suggesting that decreased power due to smaller sample size and shorter follow-up time may explain the discrepancy. Differences in the study populations (LHS, younger cohort with mild-moderate COPD; ECLIPSE, older cohort with more severe COPD and a smaller sample size) may also contribute. Additionally, we did not find a significant relationship between serum CC-16 level and change in FEV1 in the ECLIPSE study alone, which is in contrast to previous analyses. [9] This may be due to differences in the models used to determine change in FEV1.
Nevertheless, the statistically non-significant trend was in the same direction as previously reported effects of serum CC-16 level on change in FEV1. [9, 10] Further studies in larger, independent cohorts will be needed to confirm the causal effect of serum CC-16 level on change in FEV1.
Although MR analysis suggests a causal effect of serum CC-16 level on COPD outcomes, we took steps to ensure the causal inferences do not violate the fundamental assumptions of MR. [21] These steps included: 1) accounting for linkage disequilibrium structure between the SNPs included in MR analysis, to ensure the instrumental variables were independently associated with serum CC-16 level;
2) testing for heterogeneity, the presence of which would suggest that variability in the SNP associations is greater than would be expected by chance alone and thus may indicate bias; and 3) testing for evidence of directional pleiotropy i.e. one or more of the instrumental variables is associated with the outcome via a risk factor other than serum CC-16, through MR-Egger and MR-PRESSO analyses. When the MR estimates for the effects of serum CC-16 level on both COPD risk and progression were significant, these statistical tests for heterogeneity and directional pleiotropy were not significant, suggesting no major violation of the MR assumptions.
Our results complement previous in vitro and animal studies investigating a causal role for CC-16 in COPD pathogenesis. Among the most convincing evidence is the study by Laucho-Contreras and colleagues [3] in which CC-16-/-knockout mice showed signs of accelerated emphysema-like lung 22 changes, airway remodelling, alveolar apoptosis, and increased lung inflammation following cigarette smoke exposure. These effects were attenuated by transfection with a CC-16-producing adenoviral vector. However, these changes were not observed in a similar study by Park and colleagues, despite the use of an identical strain of mouse and a similar experimental design. [10] The reasons for this discrepancy are unclear. Our results therefore contribute important evidence from human studies that CC-16 is implicated in the development and progression of COPD.
CONCLUSION
Using GWAS and the MR framework, we have provided evidence for a potential causal effect of serum CC-16 level in COPD pathogenesis and lung function decline. These results complement previous attempts to establish a causal role for CC-16 in animal models. Further investigation of serum CC-16 as a biomarker, and its potential as a therapeutic target, in COPD is warranted.
